APIM Therapeutics is developing a series of proprietary Protein Protein Interaction (PPI) blocking peptides targeting complexes formed between PCNA1 (Proliferating Cell Nuclear Antigen) and proteins bearing a novel PCNA-interacting Peptide Motif called APIM2 (AlkB homolog 2 PCNA Interacting Motif). These compounds are particularly relevant for the treatment of hyper-proliferative disorders such as cancer.

Our therapeutic candidate, ATX-101, is a first-in class PCNA/APIM PPI blocking compound that has recently reached the clinical stage. ATX-101 is being developed for the treatment of several cancer indications either alone or in combination with selected anti-cancer agents. A snapshot of the drug pipeline of APIM Therapeutics is presented below. The company has a strong interest in multiple myeloma and bladder cancer (advanced and localized/superficial). Other indications/combinations are also of further interest for future applications.

pipeline overview

For more information on our pipeline, feel free to contact us directly.